Cerus Corp CERS
We take great care to ensure that the data presented and summarized in this overview for CERUS CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CERS
View all-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl20.8MShares$30.2 Million0.28% of portfolio
-
Baker Bros. Advisors LP New York, NY19.5MShares$28.2 Million0.33% of portfolio
-
Black Rock Inc. New York, NY13.9MShares$20.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.4MShares$15.1 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT8.32MShares$12.1 Million0.06% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.6.46MShares$9.37 Million0.01% of portfolio
-
Nikko Asset Management Americas, Inc.6.46MShares$9.37 Million0.11% of portfolio
-
Senvest Management, LLC New York, NY6.39MShares$9.27 Million0.3% of portfolio
-
Geode Capital Management, LLC Boston, MA4.45MShares$6.46 Million0.0% of portfolio
-
State Street Corp Boston, MA3.8MShares$5.52 Million0.0% of portfolio
Latest Institutional Activity in CERS
Top Purchases
Top Sells
About CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Insider Transactions at CERS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 14
2025
|
William Mariner Greenman President and CEO |
SELL
Open market or private sale
|
Direct |
122,827
-2.9%
|
$122,827
$1.45 P/Share
|
Mar 14
2025
|
Vivek K Jayaraman Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
46,004
-3.11%
|
$46,004
$1.45 P/Share
|
Mar 14
2025
|
Chrystal Menard Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
30,075
-3.7%
|
$30,075
$1.45 P/Share
|
Mar 14
2025
|
Richard J Benjamin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
30,075
-4.2%
|
$30,075
$1.45 P/Share
|
Mar 14
2025
|
Kevin Dennis Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
36,740
-4.03%
|
$36,740
$1.45 P/Share
|
Mar 13
2025
|
William Mariner Greenman President and CEO |
SELL
Open market or private sale
|
Direct |
71,086
-1.65%
|
$71,086
$1.45 P/Share
|
Mar 13
2025
|
Vivek K Jayaraman Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
29,985
-1.99%
|
$29,985
$1.45 P/Share
|
Mar 13
2025
|
Chrystal Menard Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
18,949
-2.28%
|
$18,949
$1.45 P/Share
|
Mar 13
2025
|
Richard J Benjamin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
18,949
-2.58%
|
$18,949
$1.45 P/Share
|
Mar 13
2025
|
Kevin Dennis Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
23,147
-2.47%
|
$23,147
$1.45 P/Share
|
Mar 07
2025
|
William Mariner Greenman President and CEO |
SELL
Open market or private sale
|
Direct |
60,984
-1.4%
|
$60,984
$1.5 P/Share
|
Mar 07
2025
|
Vivek K Jayaraman Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
33,999
-2.21%
|
$33,999
$1.5 P/Share
|
Mar 07
2025
|
Chrystal Menard Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
27,457
-3.19%
|
$27,457
$1.5 P/Share
|
Mar 07
2025
|
Richard J Benjamin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
26,139
-3.44%
|
$26,139
$1.5 P/Share
|
Mar 07
2025
|
Kevin Dennis Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
31,148
-3.22%
|
$31,148
$1.5 P/Share
|
Mar 06
2025
|
William Mariner Greenman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,140,742
+11.24%
|
-
|
Mar 06
2025
|
Vivek K Jayaraman Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
635,486
+16.43%
|
-
|
Mar 06
2025
|
Chrystal Menard Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
454,577
+20.12%
|
-
|
Mar 06
2025
|
Richard J Benjamin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
366,565
+19.11%
|
-
|
Mar 06
2025
|
Kevin Dennis Green Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
473,040
+19.19%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 3.45M shares |
---|---|
Open market or private purchase | 28.7K shares |
Exercise of conversion of derivative security | 128K shares |
Open market or private sale | 992K shares |
---|